November 2016- Volume 12, Issue 11

November 2016

In this Issue

Clinical Trials

A Phase 1, 2 punch to Parkinson’s disease

A Phase 1, 2 punch to Parkinson’s disease

Phase 1 clinical trial shows PXT002331 to be a potential weapon against Parkinson’s disease

An ACTIVE accomplishment

An ACTIVE accomplishment

Radius’ abaloparatide-SC reduces fractures, boosts bone mineral density in postmenopausal women with osteoporosis

Romosozumab impresses in osteoporosis trial

Romosozumab impresses in osteoporosis trial

FRAME study demonstrates effectiveness of drug that binds and inhibits activity of sclerostin

Managing migraine

Managing migraine

Drug treats migraine symptoms without cardiovascular risk

Going after Crohn’s and colitis

Going after Crohn’s and colitis

Celgene announces positive data from two studies of oral therapies for the gastrointestinal conditions

Preclinical

Vaxonella vs. Zika

Vaxonella vs. Zika

Prokarium seeks to develop world’s first oral vaccine against Zika virus

A new cancer combination

A new cancer combination

AsiDNA and PARP inhibitors demonstrate synergistic effect, bypass genetic restriction

It’s all in the presentation

It’s all in the presentation

A quick roundup of some recent preclinical data presentations

A new option for Sanfilippo?

A new option for Sanfilippo?

Abeona’s preclinical data support gene therapy for rare disorder MPS IIIA

Discovery

The eyes have it

The eyes have it

Indiana U. wins $1.9M NIH grant for blindness prevention through research on photoreceptors

A new partnership ‘Blooms’ for 3D models

A new partnership ‘Blooms’ for 3D models

Plasticell and CellSpring collaborate on tissue models for drug candidate screening

U.K. drug discovery landscape in fundamental shift

U.K. drug discovery landscape in fundamental shift

According to a new report, the British drug arena is headed more toward collaboration and open innovation

Tarveda licenses HSP90 drug conjugate platform

Tarveda licenses HSP90 drug conjugate platform

Deal with Madrigal Pharmaceuticals could be worth in excess of $249 million

Business & Government Policy

Next- generation cancer partnership

Next- generation cancer partnership

Investigational therapy uses an oncolytic virus platform to infect and break down cancer

Off the shelf and into the lab

Off the shelf and into the lab

Fate Therapeutics and Memorial Sloan Kettering to develop off-the-shelf T cell product candidates

On the cutting edge

On the cutting edge

A roundup of instrumentation, software and other tools and technology news

Patent Docs: Scope of Hatch-Waxman ‘safe harbor’ remains unclear

Patent Docs: Scope of Hatch-Waxman ‘safe harbor’ remains unclear

The question of whether activities undertaken post-approval are subject to the act has not been subject to Supreme Court review and recently it declined such review in a specific case

Diagnostics

Putting cancer breath test through the paces

Putting cancer breath test through the paces

Owlstone Medical embarks on world’s largest clinical trial for breath-based lung cancer detection

Bone breakthrough

Bone breakthrough

Austrian company demonstrates miRNA-based test for early detection of osteoporosis

Cancer Genetics and BARC launch partnership

Cancer Genetics and BARC launch partnership

Initial focus will be on immuno-oncology, hematological cancers and lung cancer

Meeting up for MDx

Meeting up for MDx

New Agilent/Burning Rock deal to focus on cancer diagnostics

Contract Services

Bracket gets random with integrated PBD technology

Bracket gets random with integrated PBD technology

Clinical trial tech and services company becomes first clinical IRT provider to natively integrate PBD

PAREXEL acquires ExecuPharm to broaden functional service depth

PAREXEL acquires ExecuPharm to broaden functional service depth

Deal is part of ongoing effort to serve a broader customer base of varying sizes with varying abilities

Ideathon makes an ‘Inspiring’ first showing

Ideathon makes an ‘Inspiring’ first showing

The ‘Inspiring Hope’ Ideathon crowdsources ideas for boosting clinical trial awareness and participation

Exco InTouch boasts quadrupled growth

Exco InTouch boasts quadrupled growth

September saw Exco InTouch celebrate its recognition on the Sunday Times Hiscox Tech Track 100

Research & Development

‘A one-step, one-flask process’

‘A one-step, one-flask process’

Scientists stumble upon revolutionary process in drug design and synthesis

Headway on HIV

Headway on HIV

TSRI identifies Env ‘holes’ and bnAbs as potential new approaches in targeting HIV

A duo for single-cell sequencing

A duo for single-cell sequencing

TTP Labtech/UC San Diego collaboration accelerates single-cell genomics research

Pair of grants for a protein program

Pair of grants for a protein program

Inventiva nets €2.3 million to pursue YAP/TEAD research

Editor's Focus

An update on Cancer Moonshot efforts

An update on Cancer Moonshot efforts

The Cancer Moonshot program launched in January by President Barack Obama is something we've been covering here and there in DDNews, and now we catch you up on some of the latest activities

Commentary

Out of order: Being human

Out of order: Being human

There is certainly value to finding ways to alleviate some of the most challenging and debilitating aspects of autism, but DDNews Features Editor Randall C Willis offers a suggestion: Maybe we shouldn't be trying to actually 'cure' autism per se

Guest Commentary: Accelerating discovery through contract chemical synthesis

Guest Commentary: Accelerating discovery through contract chemical synthesis

Contract chemistry laboratories are playing an increasingly important role in pharma R&D, and Jeremiah Malerich and colleagues from SRI International share their insights about the role contract chemistry plays in drug discovery

Feature

Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

November 2023 magazine issue front cover

Latest Issue  

• Volume 19 • Issue 11 • November 2023

November 2023

November 2023 Issue